Under: Fat Loss
Best Peptides for Visceral Fat Reduction
Targeting deep abdominal fat surrounding organs, associated with metabolic risk.
Visceral fat—the metabolically active adipose tissue surrounding abdominal organs—is associated with insulin resistance, inflammation, and metabolic dysfunction. Research peptides are being studied for their ability to target this deep abdominal fat through distinct mechanisms: AOD-9604 works directly on adipose tissue to stimulate lipolysis and inhibit fat accumulation independent of growth hormone effects, while Retatrutide employs triple receptor activation (GLP-1, GIP, and glucagon) to reduce appetite, improve insulin sensitivity, and increase energy expenditure simultaneously.
Research protocols typically involve subcutaneous administration on regular schedules, often weekly or multiple times weekly depending on the peptide, with duration varying from 8 to 16+ weeks in clinical studies. Dosing considerations include body composition baseline, metabolic health markers, and concurrent lifestyle factors such as diet and exercise, which substantially influence outcomes in research settings.
Peptides Studied for Visceral Fat Reduction
| Peptide | Evidence | Notes | Actions |
|---|---|---|---|
| Retatrutide Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. Phase 2 trials showed unprecedented weight loss of up to 24% at 48 weeks, making it potentially the most effective obesity treatment studied. | high | — | |
| Retatrutide Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. Phase 2 trials showed unprecedented weight loss of up to 24% at 48 weeks, making it potentially the most effective obesity treatment studied. | high | — | |
| AOD-9604 AOD-9604 is a modified fragment of human growth hormone (HGH fragment 176-191). It was developed to have the fat-reducing effects of growth hormone without the adverse effects on blood sugar or growth. | medium | — | |
| AOD-9604 AOD-9604 is a modified fragment of human growth hormone (HGH fragment 176-191). It was developed to have the fat-reducing effects of growth hormone without the adverse effects on blood sugar or growth. | medium | — |
Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. Phase 2 trials showed unprecedented weight loss of up to 24% at 48 weeks, making it potentially the most effective obesity treatment studied.
Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. Phase 2 trials showed unprecedented weight loss of up to 24% at 48 weeks, making it potentially the most effective obesity treatment studied.
AOD-9604 is a modified fragment of human growth hormone (HGH fragment 176-191). It was developed to have the fat-reducing effects of growth hormone without the adverse effects on blood sugar or growth.